MedPath

Efficacy and Safety of Erenumab in Pediatric Participants With Episodic Migraine

Phase 3
Recruiting
Conditions
Migraine
Interventions
Registration Number
NCT03836040
Lead Sponsor
Amgen
Brief Summary

This study will evaluate the efficacy and safety of erenumab in migraine prevention in children (6 to \<12 years) and adolescents (12 to \<18 years) with episodic migraine. The study hypothesis is that in pediatric participants with episodic migraine, the combined erenumab dose group has a greater reduction from baseline to week 9 through week 12 (month 3) in monthly migraine days (MMDs) when compared with placebo in the double-blind treatment phase (DBTP).

Detailed Description

This study is a Phase 3, randomized, double-blind, placebo-controlled, parallel-group study to evaluate the efficacy and safety of erenumab in migraine prevention in children (6 to \<12 years) and adolescents (12 to \<18 years) with episodic migraine.

The trial consists of four phases: screening (up to 3 weeks of initial screening and a 4-week prospective baseline phase); the DBTP (24 weeks for Group 1 participants; 12-weeks for Group 2 participants) in which participants receive placebo or Erenumab dose 1, dose 2 or dose 3 (based on participant's body weight) via subcutaneous injection once a month; the optional dose level blinded extension phase (40 weeks), in which all participants are assigned to receive dose 1, dose 2 or dose 3 of Erenumab; and a 12 weeks safety follow-up phase (16 weeks after the last dose of investigational drug).

The study intends to enroll 456 participants (376 adolescents and up to 80 children).

Recruitment & Eligibility

Status
RECRUITING
Sex
All
Target Recruitment
456
Inclusion Criteria

Not provided

Exclusion Criteria

Not provided

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
Dose level 1Erenumab Dose 1Participants will be randomized to one of two doses determined by their body weight at Day 1. Participants who enrolled under the original protocol or protocol amendment 1 will be identified as group 1. Those enrolled under protocol amendment 2 will be identified as group 2.
Dose level 1Erenumab Dose 2Participants will be randomized to one of two doses determined by their body weight at Day 1. Participants who enrolled under the original protocol or protocol amendment 1 will be identified as group 1. Those enrolled under protocol amendment 2 will be identified as group 2.
Dose level 2Erenumab Dose 3Participants will be randomized to one of two doses determined by their body weight at Day 1. Participants who enrolled under the original protocol or protocol amendment 1 will be identified as group 1. Those enrolled under protocol amendment 2 will be identified as group 2.
Dose level 2Erenumab Dose 2Participants will be randomized to one of two doses determined by their body weight at Day 1. Participants who enrolled under the original protocol or protocol amendment 1 will be identified as group 1. Those enrolled under protocol amendment 2 will be identified as group 2.
PlaceboPlaceboParticipants will be randomized to a placebo comparator.
Primary Outcome Measures
NameTimeMethod
Change from baseline in MMDsBaseline through week 12 of the double blind treatment phase

To evaluate the effect of erenumab compared with placebo on the change in MMDs from baseline to week 9 through week 12 (month 3) of the double-blind treatment period (DBTP).

Secondary Outcome Measures
NameTimeMethod
Proportion of participants with at least 50% reduction in MMDs from baselineBaseline through week 12 of the double blind treatment phase

To evaluate the effect of erenumab compared with placebo on the proportion of participants with at least 50% reduction in MMDs from baseline to week 9 through week 12 (month 3) of the DBTP

Change in monthly headache days from baselineBaseline through week 12 of the double blind treatment phase

To evaluate the effect of erenumab compared with placebo on the change from baseline in monthly headache days to week 9 through week 12 (month 3) of the DBTP

Change in MMDs from baseline to the average of the first 3 monthsBaseline through week 12 of the double blind treatment phase

To evaluate the effect of erenumab compared with placebo on the change in MMDs from baseline to the average of the first 3 months (week 1 through week 12) of the DBTP

Change in monthly average severity of migraine attacks from baseline (measured with a visual analogue scale)Baseline through week 12 of the double blind treatment phase

To evaluate the effect of erenumab compared with placebo on the change from baseline in monthly average severity of migraine attacks to week 9 through week 12 (month 3) of the DBTP. This will be measured in a daily electronic diary (eDiary) with a visual analogue scale.

Change from baseline in migraine-related disability and productivityBaseline through week 12 of the double blind treatment phase

To evaluate the effect of erenumab compared with placebo on the change from baseline in migraine-related disability and productivity as measured by the modified PedMIDAS to week 9 through week 12 (month 3) of the DBTP.

Trial Locations

Locations (118)

Fundacion Centro de Investigacion Clinica

๐Ÿ‡จ๐Ÿ‡ด

Medellรญn, Antioquia, Colombia

Paradigm Clinical Research Center Inc

๐Ÿ‡บ๐Ÿ‡ธ

San Diego, California, United States

Childrens Hospital Colorado

๐Ÿ‡บ๐Ÿ‡ธ

Aurora, Colorado, United States

Colorado Springs Neurological Associates

๐Ÿ‡บ๐Ÿ‡ธ

Colorado Springs, Colorado, United States

New England Institute for Clinical Research

๐Ÿ‡บ๐Ÿ‡ธ

Stamford, Connecticut, United States

Childrens National Health System

๐Ÿ‡บ๐Ÿ‡ธ

Washington, District of Columbia, United States

Northwest Florida Clinical Research Group Limited Liability Company

๐Ÿ‡บ๐Ÿ‡ธ

Gulf Breeze, Florida, United States

Nicklaus Childrens Hospital

๐Ÿ‡บ๐Ÿ‡ธ

Miami, Florida, United States

Pediatric Epilepsy and Neurology Specialists

๐Ÿ‡บ๐Ÿ‡ธ

Tampa, Florida, United States

TrueBlue Clinical Research

๐Ÿ‡บ๐Ÿ‡ธ

Tampa, Florida, United States

Premiere Research Institute

๐Ÿ‡บ๐Ÿ‡ธ

West Palm Beach, Florida, United States

Rare Disease Research Center Pediatrics

๐Ÿ‡บ๐Ÿ‡ธ

Atlanta, Georgia, United States

CenExel iResearch, LLC

๐Ÿ‡บ๐Ÿ‡ธ

Savannah, Georgia, United States

Northwestern University

๐Ÿ‡บ๐Ÿ‡ธ

Chicago, Illinois, United States

Chicago Headache Center and Research Institute

๐Ÿ‡บ๐Ÿ‡ธ

Chicago, Illinois, United States

Josephson Wallack Munshower Neurology

๐Ÿ‡บ๐Ÿ‡ธ

Indianapolis, Indiana, United States

University of Maryland, Baltimore

๐Ÿ‡บ๐Ÿ‡ธ

Baltimore, Maryland, United States

New England Regional Headache Center Inc

๐Ÿ‡บ๐Ÿ‡ธ

Worcester, Massachusetts, United States

Michigan Head Pain and Neurological Institute

๐Ÿ‡บ๐Ÿ‡ธ

Ann Arbor, Michigan, United States

Clinical Research Institute Inc

๐Ÿ‡บ๐Ÿ‡ธ

Minneapolis, Minnesota, United States

Childrens Mercy Hospital and Clinics

๐Ÿ‡บ๐Ÿ‡ธ

Kansas City, Missouri, United States

Mercy Research

๐Ÿ‡บ๐Ÿ‡ธ

Saint Louis, Missouri, United States

Velocity Clinical Research, Inc

๐Ÿ‡บ๐Ÿ‡ธ

Grand Island, Nebraska, United States

Dent Neurosciences Research Center

๐Ÿ‡บ๐Ÿ‡ธ

Amherst, New York, United States

Columbia University Irving Medical Center

๐Ÿ‡บ๐Ÿ‡ธ

New York, New York, United States

Cincinnati Childrens Hospital Medical Center

๐Ÿ‡บ๐Ÿ‡ธ

Cincinnati, Ohio, United States

Cleveland Clinic Foundation

๐Ÿ‡บ๐Ÿ‡ธ

Cleveland, Ohio, United States

Nationwide Childrens Hospital

๐Ÿ‡บ๐Ÿ‡ธ

Columbus, Ohio, United States

Oregon Health and Science University

๐Ÿ‡บ๐Ÿ‡ธ

Portland, Oregon, United States

Childrens Hospital of Philadelphia

๐Ÿ‡บ๐Ÿ‡ธ

Philadelphia, Pennsylvania, United States

Preferred Primary Care Physicians, Inc

๐Ÿ‡บ๐Ÿ‡ธ

Pittsburgh, Pennsylvania, United States

Palmetto Gastroenterology Clinical Research, LLC

๐Ÿ‡บ๐Ÿ‡ธ

Summerville, South Carolina, United States

Child Neurology Consultants of Austin

๐Ÿ‡บ๐Ÿ‡ธ

Austin, Texas, United States

Helios Clinical Research Inc

๐Ÿ‡บ๐Ÿ‡ธ

Burleson, Texas, United States

Servicios de Salud Ips Suramericana Sas - Ips Sura Industriales

๐Ÿ‡จ๐Ÿ‡ด

Medellin, Antioquia, Colombia

Stryde Consulting LLC

๐Ÿ‡บ๐Ÿ‡ธ

Frisco, Texas, United States

Childrens Specialty Group

๐Ÿ‡บ๐Ÿ‡ธ

Norfolk, Virginia, United States

Vaught Neurological Services

๐Ÿ‡บ๐Ÿ‡ธ

Crab Orchard, West Virginia, United States

Marshfield Clinic

๐Ÿ‡บ๐Ÿ‡ธ

Marshfield, Wisconsin, United States

Universitair Ziekenhuis Brussel

๐Ÿ‡ง๐Ÿ‡ช

Brussel, Belgium

Algemeen Ziekenhuis Sint-Maarten

๐Ÿ‡ง๐Ÿ‡ช

Mechelen, Belgium

Docteur Simona Sava

๐Ÿ‡ง๐Ÿ‡ช

Saint Nicolas, Belgium

Stollery Childrens Hospital

๐Ÿ‡จ๐Ÿ‡ฆ

Edmonton, Alberta, Canada

London Health Sciences Centre

๐Ÿ‡จ๐Ÿ‡ฆ

London, Ontario, Canada

Childrens Hospital of Eastern Ontario

๐Ÿ‡จ๐Ÿ‡ฆ

Ottawa, Ontario, Canada

The Hospital For Sick Children

๐Ÿ‡จ๐Ÿ‡ฆ

Toronto, Ontario, Canada

Institucion Prestadora de Servicios de Salud Sociedad Mรฉdica Rionegro SA Somer SA

๐Ÿ‡จ๐Ÿ‡ด

Rionegro, Antioquia, Colombia

Solano y Terront Servicios Medicos SAS - Unidad Integral de Endocrinologia Uniendo

๐Ÿ‡จ๐Ÿ‡ด

Bogota, Cundinamarca, Colombia

Cafam

๐Ÿ‡จ๐Ÿ‡ด

Bogota, Cundinamarca, Colombia

Fundacion Hospital Infantil Universitario De San Jose

๐Ÿ‡จ๐Ÿ‡ด

Bogota, Cundinamarca, Colombia

Fundacion cardiovascular de Colombia

๐Ÿ‡จ๐Ÿ‡ด

Bucaramanga, Santander, Colombia

Terveystalo Pulssi

๐Ÿ‡ซ๐Ÿ‡ฎ

Turku, Finland

Charite - Universitaetsmedizin Berlin, Campus Virchow

๐Ÿ‡ฉ๐Ÿ‡ช

Berlin, Germany

Universitaetsklinikum Essen

๐Ÿ‡ฉ๐Ÿ‡ช

Essen, Germany

Universitaetsklinikum Greifswald

๐Ÿ‡ฉ๐Ÿ‡ช

Greifswald, Germany

Schmerzklinik Kiel

๐Ÿ‡ฉ๐Ÿ‡ช

Kiel, Germany

Arzneimittelforschung Leipzig GmbH

๐Ÿ‡ฉ๐Ÿ‡ช

Leipzig, Germany

Dr Kenessey Albert Korhaz - Rendelointezet

๐Ÿ‡ญ๐Ÿ‡บ

Balassagyarmat, Hungary

Dr Altmann Anna egyeni vallalkozo

๐Ÿ‡ญ๐Ÿ‡บ

Budapest, Hungary

High Tech Medical Kft

๐Ÿ‡ญ๐Ÿ‡บ

Budapest, Hungary

Semmelweis Egyetem

๐Ÿ‡ญ๐Ÿ‡บ

Budapest, Hungary

Debreceni Egyetem Klinikai Kozpont

๐Ÿ‡ญ๐Ÿ‡บ

Debrecen, Hungary

Borsod-Abauj-Zemplen Varmegyei Kozponti Korhaz es Egyetemi Oktatokorhaz

๐Ÿ‡ญ๐Ÿ‡บ

Miskolc, Hungary

Fondazione IRCCS Istituto Neurologico Carlo Besta

๐Ÿ‡ฎ๐Ÿ‡น

Milano, Italy

Azienda di Rilievo Nazionale e Alta Specializzazione Civico Di Cristina Benfratelli

๐Ÿ‡ฎ๐Ÿ‡น

Palermo, Italy

Fondazione Istituto Neurologico Nazionale C Mondino IRCCS

๐Ÿ‡ฎ๐Ÿ‡น

Pavia, Italy

IRCCS Ospedale Pediatrico Bambino Gesu

๐Ÿ‡ฎ๐Ÿ‡น

Roma, Italy

Josai Kids Clinic

๐Ÿ‡ฏ๐Ÿ‡ต

Nagoya-shi, Aichi, Japan

Medical Corporation Seikokai Takanoko Hospital

๐Ÿ‡ฏ๐Ÿ‡ต

Matsuyama-shi, Ehime, Japan

Hiroshima City Hiroshima Citizens Hospital

๐Ÿ‡ฏ๐Ÿ‡ต

Hiroshima-shi, Hiroshima, Japan

Kitami Clinic

๐Ÿ‡ฏ๐Ÿ‡ต

Sapporo-shi, Hokkaido, Japan

Konan Medical Center

๐Ÿ‡ฏ๐Ÿ‡ต

Kobe-shi, Hyogo, Japan

Umenotsuji Clinic

๐Ÿ‡ฏ๐Ÿ‡ต

Kochi-shi, Kochi, Japan

Kumamoto City Hospital

๐Ÿ‡ฏ๐Ÿ‡ต

Kumamoto-shi, Kumamoto, Japan

Tatsuoka Neurology Clinic

๐Ÿ‡ฏ๐Ÿ‡ต

Kyoto-shi, Kyoto, Japan

Japanese Red Cross Kyoto Daiichi Hospital

๐Ÿ‡ฏ๐Ÿ‡ต

Kyoto-shi, Kyoto, Japan

Ishikawa Clinic

๐Ÿ‡ฏ๐Ÿ‡ต

Kyoto-shi, Kyoto, Japan

Sendai Headache and Neurology Clinic

๐Ÿ‡ฏ๐Ÿ‡ต

Sendai-shi, Miyagi, Japan

Tominaga Hospital

๐Ÿ‡ฏ๐Ÿ‡ต

Osaka-shi, Osaka, Japan

Saitama Neuropsychiatric Institute

๐Ÿ‡ฏ๐Ÿ‡ต

Saitama-shi, Saitama, Japan

Tokyo Medical University Hospital

๐Ÿ‡ฏ๐Ÿ‡ต

Shinjuku-ku, Tokyo, Japan

Keio University Hospital

๐Ÿ‡ฏ๐Ÿ‡ต

Shinjuku-ku, Tokyo, Japan

Nagamitsu Clinic

๐Ÿ‡ฏ๐Ÿ‡ต

Hofu-shi, Yamaguchi, Japan

Nagaseki Headache Clinic

๐Ÿ‡ฏ๐Ÿ‡ต

Kai-shi, Yamanashi, Japan

Uniwersytecki Dzieciecy Szpital Kliniczny im Ludwika Zamenhofa w Bialymstoku

๐Ÿ‡ต๐Ÿ‡ฑ

Bialystok, Poland

AthleticoMed

๐Ÿ‡ต๐Ÿ‡ฑ

Bydgoszcz, Poland

Uniwersyteckie Centrum Kliniczne

๐Ÿ‡ต๐Ÿ‡ฑ

Gdansk, Poland

Instytut Centrum Zdrowia Matki Polki

๐Ÿ‡ต๐Ÿ‡ฑ

Lodz, Poland

Centrum Medyczne Luxmed Spzoo

๐Ÿ‡ต๐Ÿ‡ฑ

Lublin, Poland

Centrum Medyczne Hope Clinic Sebastian Szklener

๐Ÿ‡ต๐Ÿ‡ฑ

Lublin, Poland

Uniwersytecki Szpital Kliniczny w Poznaniu

๐Ÿ‡ต๐Ÿ‡ฑ

Poznan, Poland

Clinical Research Center Spzoo Medic-R Spolka Komandytowa

๐Ÿ‡ต๐Ÿ‡ฑ

Poznan, Poland

Dr Sekowska Leczenie Bolu

๐Ÿ‡ต๐Ÿ‡ฑ

Warszawa, Poland

Next Stage Spzoo

๐Ÿ‡ต๐Ÿ‡ฑ

Warszawa, Poland

Migre Polskie Centrum Leczenia Migreny Anna Gryglas-Dworak

๐Ÿ‡ต๐Ÿ‡ฑ

Wroclaw, Poland

Unidade Local de Saude de Coimbra, EPE - Hospital Pediatrico de Coimbra

๐Ÿ‡ต๐Ÿ‡น

Coimbra, Portugal

Unidade Local de Saude de Sao Jose, EPE - Hospital Dona Estefania

๐Ÿ‡ต๐Ÿ‡น

Lisboa, Portugal

Hospital da Luz, SA

๐Ÿ‡ต๐Ÿ‡น

Lisboa, Portugal

Unidade Local de Saude de Santa Maria, EPE - Hospital de Santa Maria

๐Ÿ‡ต๐Ÿ‡น

Lisboa, Portugal

Puerto Rico Health and Wellness Institute

๐Ÿ‡ต๐Ÿ‡ท

Dorado, Puerto Rico

FSBI Russian Children Clinical Hospital of the MoH RF

๐Ÿ‡ท๐Ÿ‡บ

Moscow, Russian Federation

LLC clinic Chaika

๐Ÿ‡ท๐Ÿ‡บ

Moscow, Russian Federation

LLC Sibneyromed

๐Ÿ‡ท๐Ÿ‡บ

Novosibirsk, Russian Federation

LLC Medical Technologies

๐Ÿ‡ท๐Ÿ‡บ

Saint Petersburg, Russian Federation

Hospital Universitario Virgen del Rocio

๐Ÿ‡ช๐Ÿ‡ธ

Sevilla, Andalucรญa, Spain

Hospital Universitari Vall d Hebron

๐Ÿ‡ช๐Ÿ‡ธ

Barcelona, Cataluรฑa, Spain

Hospital de la Santa Creu i Sant Pau

๐Ÿ‡ช๐Ÿ‡ธ

Barcelona, Cataluรฑa, Spain

Hospital Universitari i Politecnic La Fe

๐Ÿ‡ช๐Ÿ‡ธ

Valencia, Comunidad Valenciana, Spain

Clinica Universidad de Navarra

๐Ÿ‡ช๐Ÿ‡ธ

Pamplona, Navarra, Spain

Universitaets-Kinderspital beider Basel

๐Ÿ‡จ๐Ÿ‡ญ

Basel, Switzerland

Kopfwehzentrum Hirslanden

๐Ÿ‡จ๐Ÿ‡ญ

Zollikon, Switzerland

Noahs Ark Childrens Hospital for Wales

๐Ÿ‡ฌ๐Ÿ‡ง

Cardiff, United Kingdom

Royal Hospital for Children

๐Ÿ‡ฌ๐Ÿ‡ง

Glasgow, United Kingdom

Alder Hey Childrens Hospital

๐Ÿ‡ฌ๐Ÿ‡ง

Liverpool, United Kingdom

Evelina Childrens Hospital

๐Ÿ‡ฌ๐Ÿ‡ง

London, United Kingdom

Great Ormond Street Hospital for Children

๐Ÿ‡ฌ๐Ÿ‡ง

London, United Kingdom

4 Medical Clinical Solutions Manchester

๐Ÿ‡ฌ๐Ÿ‡ง

Manchester, United Kingdom

Oxford Childrens Hospital

๐Ÿ‡ฌ๐Ÿ‡ง

Oxford, United Kingdom

ยฉ Copyright 2025. All Rights Reserved by MedPath